Respiratory Drugs Market by Distribution Channel, Type and Geography - Forecast and Analysis 2023-2027

Published: Sep 2023

Pages: 170

SKU: IRTNTR73197

Snapshot

Respiratory Drugs Market 2023-2027

The Respiratory Drugs Market size is estimated to grow by USD 30.23 billion at a CAGR of 6.38% between 2022 and 2027.

There is an increasing demand for sustainable and safe respiratory drugs across the world. One of the leading causes of death across the globe is respiratory disease with asthma being the most prevalent disease and affects people of all ages. Even though there are numerous therapies, a majority of the population across the globe is living with poorly controlled respiratory diseases and have a low quality of life. As a result, there is an increase in investments for the innovation of respiratory drugs globally which is positively impacting the market.

Technavio has segmented the market into Distribution Channels, Types, and Geography

The distribution channel segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies.
The type segment is classified into asthma, COPD, allergic rhinitis, cystic fibrosis, and other respiratory diseases.
The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW).

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Respiratory Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

Respiratory Drugs Market Segmentation by Distribution Channel, Type and Geography Analysis

Distribution Channel Analysis

Hospital pharmacies

The hospital pharmacies segment is estimated to witness significant growth during the forecast period. Several hospital pharmacies collaborate with many suppliers and pharmaceutical companies to procure the necessary respiratory drugs. After procurement, these drugs are then stored in the pharmacy inventory. The main purpose of inventory management systems is that it helps to track stock levels and ensure that a sufficient supply of respiratory medications is available.

Get a glance at the market contribution of various segments View a PDF Sample

The hospital pharmacies segment was the largest segment and was valued at USD 33.90 billion in 2017. One of the major aspects of healthcare is accurate documentation such that several hospital pharmacies maintain records of the medications dispensed to each patient. As a result, it helps in monitoring the patient's treatment progress and ensures accountability. Additionally, this segment is also involved in tracking the patient's response to the prescribed respiratory drugs. Furthermore, this segment often educates patients on how to effectively use respiratory medications. As a result, this guidance significantly contributes to better patient adherence and more effective drug distribution. Hence, such factors are expected to fuel the growth of this segment which, in turn, will drive the market growth during the forecast period.

Type Analysis

Asthma

Some of the key respiratory drugs that have increased focus on asthma include SYMBICORT, PULMICORT, Relvar Ellipta/Breo Ellipta, ARUNITY ELLIPTA, NUCALA, Seretide/Advair, and XOLAIR. There is an increasing prevalence of asthma across the globe. There is a huge market potential for asthma as prominent companies such as AstraZeneca and Novartis are planning to launch new drugs in the coming years. In addition, there are significant ongoing developments in this segment which is positively impact the market. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

COPD

Some of the prominent products launched by market players which are operating in this market include BEVESPI AEROSPHERE, DELIRESP/DAXAS, and SYMBICORT by AstraZeneca; Flixotide/FLOVENT, INCRUSE ELLIPTA, and RELVAR/BREO ELLIPTA by GlaxoSmithKline; and Onbrez Breezhaler and Seebri Breezhaler by Novartis. Factors such as the increasing presence of several drugs in the market, the approval of new drugs including TRELEGY ELLIPTA and Duaklir Genuair, and the progress in the development of new drugs such as AZD9412 for COPD is expected to significantly contribute to the growth of this segment. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. One of the main factors that is significantly contributing to the growth of the global respiratory drugs market in North America is the aging demographic, which increases the prevalence of respiratory diseases. There is an increasing demand for more respiratory medications and healthcare services for the growing elderly population in the region, especially in the US and Canada.

For instance, as per the American College of Allergy, Asthma and Immunology, as of 2023, 8.3% of Americans have asthma. 20.4 million of these 26.5 million are adults, and 6.1 million are kids. The prevalence of asthma is higher in children (9.4%) than in adults (7.7%), and it is higher in females (9.2%) than in males (7.0%). In addition, poor air quality fuels the demand for effective respiratory drugs to manage symptoms and enhance patients' quality of life. Hence, such factors are expected to drive the market growth in the region during the forecast period.

COVID Recovery Analysis

In 2020, during the COVID-19 pandemic, the growth of the global respiratory drugs market witnessed a significant slowdown as various non-urgent treatments were either given in a limited capacity or completely closed as per guidelines as well and some scheduled treatments were either delayed or postponedin North America. However, in 2021, the initiation of large-scale vaccination drives lifted the lockdown and travel restrictions, which led to the resumption of business activities and the re-opening of offline retail pharmacies. Such factors are expected to drive the market during the forecast period.

Buy Now Full Report and Discover More

Key Respiratory Drugs Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories: The company offers respiratory drugs namely Pulmocare designed for people with chronic obstructive pulmonary disease, cystic fibrosis, or respiratory failure.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Respiratory Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Respiratory Drugs Market Drivers

One of the key factors driving the respiratory drugs market growth is the rising prevalence of respiratory diseases. There is an increasing prevalence of respiratory diseases across the globe which has significantly contributed to the growth of the global respiratory drugs market. The strong demand for innovative solutions that can improve disease management and enhance patients' quality of life is fuelled by conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Moreover, respiratory diseases comprise a wide range of conditions impacting the lungs and airways, such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, bronchitis, and more. In addition, there is a high chance of respiratory diseases due to poor air quality, often due to environmental pollution, especially due to environmental pollution. Hence, such factors are expected to positively impact the market. Therefore, it is expected to drive the market growth during the forecast period.

Significant Respiratory Drugs Market Trends

A key factor shaping the respiratory drugs market growth is the emergence of telehealth and remote monitoring. There was an increasing adoption of telehealth services during the COVID-19 pandemic which has revolutionized healthcare delivery. The main features of telehealth are that it facilitates remote consultations, diagnosis, treatment, and monitoring for respiratory patients, enhancing access to care.

Moreover, it also enables respiratory patients to consult pulmonologists and other specialists virtually. There is an increasing adoption of telehealth by healthcare providers to diagnose and assess respiratory conditions remotely, using video consultations, patient histories, and shared medical data. Hence, such factors are positively impacting the market which in turn will drive the market growth during the forecast period.

Key Respiratory Drugs Market Challenges

Concerns associated with screening and diagnosis are one of the key challenges hindering the respiratory drugs market growth. There is an increasing prevalence of respiratory diseases, both acute and chronic which is significantly impacting the population across the globe even though there are significant advancements in understanding the complex pathophysiology of respiratory disease and the availability of medical therapies. One of the main reasons is the challenges related to screening and diagnosing respiratory diseases, such as pulmonary arterial hypertension (PAH).

Moreover, due to the inaccurate diagnosis, it is highly unlikely the patient will receive appropriate treatment. One of the major challenges that must be overcome is the delayed diagnosis of PAH. The main factor which is leading to delayed diagnosis is the symptoms of PAH including fatigue, weakness, and breathlessness, which overlap with symptoms of other disorders such as COPD and asthma. Hence, such factors are negatively impacting the market which in turn will hinder the market growth during the forecast period.

Buy Now Full Report and Discover More

Key Respiratory Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Respiratory Drugs Market Customer Landscape

Segment Overview

The respiratory drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Distribution Channel Outlook (USD Billion, 2017 - 2027)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Type Outlook (USD Billion, 2017 - 2027)
- Asthma
- COPD
- Allergic rhinitis
- Cystic fibrosis
- Other respiratory diseases
Geography Outlook (USD Billion, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Australia
  - Argentina
  - Brazil

Respiratory Drugs Market Scope
Report Coverage	Details
Page number	170
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.38%
Market growth 2023-2027	USD 30.23 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	5.51
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 50%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., Aerogen Pharma Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Celon Pharma SA, Cipla Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Laboratory Corp. of America Holdings, Lupin Ltd., Medisol Lifescience Pvt. Ltd., Merck and Co. Inc., Novartis AG, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Wellona Pharma, and Glenmark Pharmaceuticals Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Respiratory Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the respiratory drugs market between 2023 and 2027
Precise estimation of the respiratory drugs market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of respiratory drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global respiratory drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global respiratory drugs market 2017 - 2021 ($ billion)

4.2 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ billion)

4.3 Type Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ billion)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

6.1 Market segments
- Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel

6.3 Hospital pharmacies - Market size and forecast 2022-2027
- Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

6.4 Retail pharmacies - Market size and forecast 2022-2027
- Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

6.5 Online pharmacies - Market size and forecast 2022-2027
- Exhibit 42: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

6.6 Market opportunity by Distribution Channel
- Exhibit 46: Market opportunity by Distribution Channel ($ billion)
- Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2022-2027 (%)
- Exhibit 49: Data Table on Type - Market share 2022-2027 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 Asthma - Market size and forecast 2022-2027
- Exhibit 52: Chart on Asthma - Market size and forecast 2022-2027 ($ billion)
- Exhibit 53: Data Table on Asthma - Market size and forecast 2022-2027 ($ billion)
- Exhibit 54: Chart on Asthma - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Asthma - Year-over-year growth 2022-2027 (%)

7.4 COPD - Market size and forecast 2022-2027
- Exhibit 56: Chart on COPD - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Data Table on COPD - Market size and forecast 2022-2027 ($ billion)
- Exhibit 58: Chart on COPD - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on COPD - Year-over-year growth 2022-2027 (%)

7.5 Allergic rhinitis - Market size and forecast 2022-2027
- Exhibit 60: Chart on Allergic rhinitis - Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Data Table on Allergic rhinitis - Market size and forecast 2022-2027 ($ billion)
- Exhibit 62: Chart on Allergic rhinitis - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Allergic rhinitis - Year-over-year growth 2022-2027 (%)

7.6 Cystic fibrosis - Market size and forecast 2022-2027
- Exhibit 64: Chart on Cystic fibrosis - Market size and forecast 2022-2027 ($ billion)
- Exhibit 65: Data Table on Cystic fibrosis - Market size and forecast 2022-2027 ($ billion)
- Exhibit 66: Chart on Cystic fibrosis - Year-over-year growth 2022-2027 (%)
- Exhibit 67: Data Table on Cystic fibrosis - Year-over-year growth 2022-2027 (%)

7.7 Other respiratory diseases - Market size and forecast 2022-2027
- Exhibit 68: Chart on Other respiratory diseases - Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Data Table on Other respiratory diseases - Market size and forecast 2022-2027 ($ billion)
- Exhibit 70: Chart on Other respiratory diseases - Year-over-year growth 2022-2027 (%)
- Exhibit 71: Data Table on Other respiratory diseases - Year-over-year growth 2022-2027 (%)

7.8 Market opportunity by Type
- Exhibit 72: Market opportunity by Type ($ billion)
- Exhibit 73: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 75: Chart on Market share by geography 2022-2027 (%)
- Exhibit 76: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 77: Chart on Geographic comparison
- Exhibit 78: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 79: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 80: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 81: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 83: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 84: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 85: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 87: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 88: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 89: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 95: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 96: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 97: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 Canada - Market size and forecast 2022-2027
- Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
- Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.10 China - Market size and forecast 2022-2027
- Exhibit 107: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 108: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 109: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 110: Data Table on China - Year-over-year growth 2022-2027 (%)

9.11 UK - Market size and forecast 2022-2027
- Exhibit 111: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 112: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 113: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 114: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 115: Market opportunity by geography ($ billion)
- Exhibit 116: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 117: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 118: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 119: Overview on factors of disruption

11.4 Industry risks
- Exhibit 120: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 121: Vendors covered

12.2 Market positioning of vendors
- Exhibit 122: Matrix on vendor position and classification

12.3 Abbott Laboratories
- Exhibit 123: Abbott Laboratories - Overview
- Exhibit 124: Abbott Laboratories - Business segments
- Exhibit 125: Abbott Laboratories - Key news
- Exhibit 126: Abbott Laboratories - Key offerings
- Exhibit 127: Abbott Laboratories - Segment focus

12.4 AbbVie Inc.
- Exhibit 128: AbbVie Inc. - Overview
- Exhibit 129: AbbVie Inc. - Product / Service
- Exhibit 130: AbbVie Inc. - Key news
- Exhibit 131: AbbVie Inc. - Key offerings

12.5 Aerogen Pharma Ltd.
- Exhibit 132: Aerogen Pharma Ltd. - Overview
- Exhibit 133: Aerogen Pharma Ltd. - Product / Service
- Exhibit 134: Aerogen Pharma Ltd. - Key offerings

12.6 AstraZeneca Plc
- Exhibit 135: AstraZeneca Plc - Overview
- Exhibit 136: AstraZeneca Plc - Product / Service
- Exhibit 137: AstraZeneca Plc - Key news
- Exhibit 138: AstraZeneca Plc - Key offerings

12.7 Boehringer Ingelheim International GmbH
- Exhibit 139: Boehringer Ingelheim International GmbH - Overview
- Exhibit 140: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 141: Boehringer Ingelheim International GmbH - Key news
- Exhibit 142: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 143: Boehringer Ingelheim International GmbH - Segment focus

12.8 Celon Pharma SA
- Exhibit 144: Celon Pharma SA - Overview
- Exhibit 145: Celon Pharma SA - Business segments
- Exhibit 146: Celon Pharma SA - Key offerings
- Exhibit 147: Celon Pharma SA - Segment focus

12.9 Cipla Ltd.
- Exhibit 148: Cipla Ltd. - Overview
- Exhibit 149: Cipla Ltd. - Business segments
- Exhibit 150: Cipla Ltd. - Key news
- Exhibit 151: Cipla Ltd. - Key offerings
- Exhibit 152: Cipla Ltd. - Segment focus

12.10 F. Hoffmann La Roche Ltd.
- Exhibit 153: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 154: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 155: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 156: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 157: F. Hoffmann La Roche Ltd. - Segment focus

12.11 GlaxoSmithKline Plc
- Exhibit 158: GlaxoSmithKline Plc - Overview
- Exhibit 159: GlaxoSmithKline Plc - Business segments
- Exhibit 160: GlaxoSmithKline Plc - Key news
- Exhibit 161: GlaxoSmithKline Plc - Key offerings
- Exhibit 162: GlaxoSmithKline Plc - Segment focus

12.12 Glenmark Pharmaceuticals Ltd.
- Exhibit 163: Glenmark Pharmaceuticals Ltd. - Overview
- Exhibit 164: Glenmark Pharmaceuticals Ltd. - Product / Service
- Exhibit 165: Glenmark Pharmaceuticals Ltd. - Key offerings

12.13 Lupin Ltd.
- Exhibit 166: Lupin Ltd. - Overview
- Exhibit 167: Lupin Ltd. - Product / Service
- Exhibit 168: Lupin Ltd. - Key news
- Exhibit 169: Lupin Ltd. - Key offerings

12.14 Novartis AG
- Exhibit 170: Novartis AG - Overview
- Exhibit 171: Novartis AG - Business segments
- Exhibit 172: Novartis AG - Key offerings
- Exhibit 173: Novartis AG - Segment focus

12.15 Sumitomo Pharma Co. Ltd.
- Exhibit 174: Sumitomo Pharma Co. Ltd. - Overview
- Exhibit 175: Sumitomo Pharma Co. Ltd. - Business segments
- Exhibit 176: Sumitomo Pharma Co. Ltd. - Key offerings
- Exhibit 177: Sumitomo Pharma Co. Ltd. - Segment focus

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 178: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 179: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 180: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 181: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 182: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Vertex Pharmaceuticals Inc.
- Exhibit 183: Vertex Pharmaceuticals Inc. - Overview
- Exhibit 184: Vertex Pharmaceuticals Inc. - Product / Service
- Exhibit 185: Vertex Pharmaceuticals Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 186: Inclusions checklist
- Exhibit 187: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 188: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 189: Research methodology
- Exhibit 190: Validation techniques employed for market sizing
- Exhibit 191: Information sources

13.5 List of abbreviations
- Exhibit 192: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

respiratory drugs market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis